http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+Bain+Capital+Life+Sciences+Opportunities+III%2C+LP/26924416.html si-local-file:///var/storage/secattach/20260814/26924416.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+Bain+Capital+Life+Sciences+Opportunities+III%2C+LP/26924416.html Fri, 14 Aug 2026 07:00:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+Bain+Capital+Life+Sciences+Opportunities+III%2C+LP/26924416.html si-local-file:///var/storage/secattach/20260814/26924416.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+Bain+Capital+Life+Sciences+Opportunities+III%2C+LP/26924416.html Fri, 14 Aug 2026 07:00:00 -0400 KYTX O.46871589 http://www.streetinsider.com/Earnings/Kyverna+Therapeutics%2C+Inc.+%28KYTX%29+Tops+Q2+EPS+by+45c/26907030.html <p>Kyverna Therapeutics, Inc. (NASDAQ: KYTX) reported Q2 EPS of ($0.63), $0.45 better than the analyst estimate of ($1.08).</p><p>For earnings history and earnings-related data on Kyverna Therapeutics, Inc. (KYTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=KYTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Kyverna+Therapeutics%2C+Inc.+%28KYTX%29+Tops+Q2+EPS+by+45c/26907030.html Tue, 11 Aug 2026 17:14:54 -0400 KYTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kyverna+Therapeutics%2C+++++For%3A+Jun+30/26905709.html si-local-file:///var/storage/secattach/20260811/26905709.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kyverna+Therapeutics%2C+++++For%3A+Jun+30/26905709.html Tue, 11 Aug 2026 16:08:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kyverna+Therapeutics%2C+++++For%3A+Jun+30/26905709.html si-local-file:///var/storage/secattach/20260811/26905709.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kyverna+Therapeutics%2C+++++For%3A+Jun+30/26905709.html Tue, 11 Aug 2026 16:08:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Aug+11/26905548.html si-local-file:///var/storage/secattach/20260811/26905548.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Aug+11/26905548.html Tue, 11 Aug 2026 16:05:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Aug+11/26905548.html si-local-file:///var/storage/secattach/20260811/26905548.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Aug+11/26905548.html Tue, 11 Aug 2026 16:05:00 -0400 KYTX O.46871589 http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html <p align="center"><em>FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology <br /></em></p> <p align="center"><em>On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026</em></p> <p align="center"><em>Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026</em></p> <p align="center"><em>Reiterates operating runway into 2028</em></p> <p>EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html Tue, 11 Aug 2026 16:02:00 -0400 KYTX KYTX http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html <p align="center"><em>FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology <br /></em></p> <p align="center"><em>On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026</em></p> <p align="center"><em>Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026</em></p> <p align="center"><em>Reiterates operating runway into 2028</em></p> <p>EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html Tue, 11 Aug 2026 16:02:00 -0400 KYTX KYTX http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html <p align="center"><em>FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology <br /></em></p> <p align="center"><em>On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026</em></p> <p align="center"><em>Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026</em></p> <p align="center"><em>Reiterates operating runway into 2028</em></p> <p>EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html Tue, 11 Aug 2026 16:02:00 -0400 KYTX KYTX http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html <p align="center"><em>FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology <br /></em></p> <p align="center"><em>On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026</em></p> <p align="center"><em>Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026</em></p> <p align="center"><em>Reiterates operating runway into 2028</em></p> <p>EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+Reports+Pipeline+Progress+and+Second+Quarter+2026+Financial+Results/26905444.html Tue, 11 Aug 2026 16:02:00 -0400 KYTX KYTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26834375.html si-local-file:///var/storage/secattach/20260729/26834375.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26834375.html Wed, 29 Jul 2026 15:22:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26834375.html si-local-file:///var/storage/secattach/20260729/26834375.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kyverna+Therapeutics%2C++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26834375.html Wed, 29 Jul 2026 15:22:00 -0400 KYTX O.46871589 http://www.streetinsider.com/Corporate+News/Kyverna+and+ElevateBio+sign+commercial+supply+deal+for+miv-cel/26816303.html <p>Kyverna Therapeutics (Nasdaq: KYTX) and ElevateBio have entered into a manufacturing and supply agreement covering U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna's autologous CD19-directed CAR T-cell therapy for autoimmune diseases.</p> <p>The agreement is intended to support potential product launches in stiff person syndrome (SPS) and generalized myasthenia gravis, as well as other ongoing clinical studies. Kyverna and ElevateBio have worked together for three years on process development, quality systems, and cell product manufacturing.</p> <p>Mayo Pujols, Chief Technology Officer of Kyverna, cited a clinical manufacturing success rate of more than 98% for miv-cel under ElevateBio's operations. "With ElevateBio's proven http://www.streetinsider.com/Corporate+News/Kyverna+and+ElevateBio+sign+commercial+supply+deal+for+miv-cel/26816303.html Mon, 27 Jul 2026 08:00:24 -0400 KYTX http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html <p><strong>New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel</strong></p><p>EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy.</p> <p>The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html Mon, 27 Jul 2026 08:00:00 -0400 KYTX KYTX http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html <p><strong>New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel</strong></p><p>EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy.</p> <p>The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html Mon, 27 Jul 2026 08:00:00 -0400 KYTX KYTX http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html <p><strong>New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel</strong></p><p>EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy.</p> <p>The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html Mon, 27 Jul 2026 08:00:00 -0400 KYTX KYTX http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html <p><strong>New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel</strong></p><p>EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19-directed CAR T-cell therapy.</p> <p>The new agreement provides Kyverna with flexible and scalable supply of miv-cel, supporting the Company’s potential http://www.streetinsider.com/Globe+Newswire/Kyverna+Therapeutics+and+ElevateBio+Enter+into+Commercial+Manufacturing+and+Supply+Agreement+for+Miv-cel/26816215.html Mon, 27 Jul 2026 08:00:00 -0400 KYTX KYTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+23/26816348.html si-local-file:///var/storage/secattach/20260727/26816348.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+23/26816348.html Mon, 27 Jul 2026 08:00:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+23/26816348.html si-local-file:///var/storage/secattach/20260727/26816348.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+23/26816348.html Mon, 27 Jul 2026 08:00:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+08/26749553.html si-local-file:///var/storage/secattach/20260709/26749553.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+08/26749553.html Thu, 09 Jul 2026 06:03:00 -0400 KYTX O.46871589 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+08/26749553.html si-local-file:///var/storage/secattach/20260709/26749553.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kyverna+Therapeutics%2C+++++For%3A+Jul+08/26749553.html Thu, 09 Jul 2026 06:03:00 -0400 KYTX O.46871589 http://www.streetinsider.com/Management+Changes/Kyverna+Therapeutics+names+Ritesh+Srivastava+as+chief+legal+officer/26670211.html <p>Kyverna Therapeutics (Nasdaq: KYTX) appointed Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026, according to a company statement.</p><p>Srivastava joins from BPGbio, where he served as General Counsel. Before that, he was Global Compliance Officer at Spectrum Pharmaceuticals, advising the board on corporate governance, risk management, and public company disclosure matters. He also previously served as Director of Compliance and Investigations at Avanir Pharmaceuticals.</p><p>Earlier in his career, Srivastava was a federal prosecutor with the U.S. Department of Justice, where he led investigations into healthcare fraud and anti-kickback cases. He also practiced as a litigator at Cooley LLP http://www.streetinsider.com/Management+Changes/Kyverna+Therapeutics+names+Ritesh+Srivastava+as+chief+legal+officer/26670211.html Mon, 22 Jun 2026 08:02:08 -0400 KYTX http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Appoints+Ritesh+Srivastava+as+Chief+Legal+and+Compliance+Officer%2C+Adding+Leadership+Strength+to+Support+Commercial-Stage+Transition/26670022.html <p align="left">EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization.</p> <p>“Ritesh is a key addition to Kyverna as we prepare for commercialization and http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Appoints+Ritesh+Srivastava+as+Chief+Legal+and+Compliance+Officer%2C+Adding+Leadership+Strength+to+Support+Commercial-Stage+Transition/26670022.html Mon, 22 Jun 2026 08:00:00 -0400 KYTX KYTX http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Appoints+Ritesh+Srivastava+as+Chief+Legal+and+Compliance+Officer%2C+Adding+Leadership+Strength+to+Support+Commercial-Stage+Transition/26670022.html <p align="left">EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization.</p> <p>“Ritesh is a key addition to Kyverna as we prepare for commercialization and http://www.streetinsider.com/Press+Releases/Kyverna+Therapeutics+Appoints+Ritesh+Srivastava+as+Chief+Legal+and+Compliance+Officer%2C+Adding+Leadership+Strength+to+Support+Commercial-Stage+Transition/26670022.html Mon, 22 Jun 2026 08:00:00 -0400 KYTX KYTX